{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:38:42Z","timestamp":1761896322489,"version":"build-2065373602"},"reference-count":25,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1016\/j.clml.2016.06.010","type":"journal-article","created":{"date-parts":[[2016,6,11]],"date-time":"2016-06-11T10:45:46Z","timestamp":1465641946000},"page":"577-581","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Incidence of Second Malignancies of Chronic Myeloid Leukemia During Treatment With Tyrosine Kinase Inhibitors"],"prefix":"10.1016","volume":"16","author":[{"given":"Xiu-Feng","family":"Yin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing-Han","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xia","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meng-Xia","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhi-Xin","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Jin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2016.06.010_bib1","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1001\/jamaoncol.2015.0735","article-title":"The Global Burden of Cancer 2013","volume":"1","author":"Fitzmaurice","year":"2015","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.clml.2016.06.010_bib2","first-page":"12","article-title":"Incidence survey of leukemia in China. Chinese Epidemiologic Study Group of Leukemia and Aplastic Anemia","volume":"14","year":"1992","journal-title":"Zhongguo Yi Xue Ke Xue Yuan Xue Bao"},{"key":"10.1016\/j.clml.2016.06.010_bib3","first-page":"114","article-title":"The incidence survey of leukemia in HaiAn for 15 years","volume":"18","author":"Hu","year":"2004","journal-title":"Chin Med J Comm"},{"key":"10.1016\/j.clml.2016.06.010_bib4","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.3324\/haematol.2009.021154","article-title":"Early intervention during imatinib therapy in patients with newly diagnosed chronic-phase chronic myeloid leukemia: a study of the Spanish PETHEMA group","volume":"95","author":"Cervantes","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2016.06.010_bib5","doi-asserted-by":"crossref","first-page":"453","DOI":"10.3109\/10428194.2013.806805","article-title":"The occurrence of second neoplasms after treatment with tyrosine kinase inhibitors for chronic myeloid leukemia","volume":"55","author":"Togasaki-Yoshimoto","year":"2014","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2016.06.010_bib6","doi-asserted-by":"crossref","first-page":"4353","DOI":"10.1182\/blood-2011-06-362889","article-title":"Malignancies occurring during therapy with tyrosine kinase inhibitors (TKIs) for chronic myeloid leukemia (CML) and other hematologic malignancies","volume":"118","author":"Verma","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2016.06.010_bib7","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/sj.leu.2404025","article-title":"Epidemiological analysis of second primary malignancies in more than 9500 patients treated with imatinib","volume":"20","author":"Pilot","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2016.06.010_bib8","doi-asserted-by":"crossref","first-page":"715","DOI":"10.3109\/10428194.2013.811581","article-title":"Extranodal marginal zone lymphoma arising in a patient with chronic myelogenous leukemia on long-term tyrosine kinase inhibitors","volume":"55","author":"Xu","year":"2014","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2016.06.010_bib9","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1038\/leu.2009.107","article-title":"Cytogenetic profile of de novo acute myeloid leukemia: a study based on 1432 patients in a single institution of China","volume":"23","author":"Cheng","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2016.06.010_bib10","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/j.1751-553X.2007.00962.x","article-title":"Different kinetic patterns of BCR-ABL transcript levels in imatinib-treated chronic myeloid leukemia patients after achieving complete cytogenetic response","volume":"30","author":"Qin","year":"2008","journal-title":"Int J Lab Hematol"},{"key":"10.1016\/j.clml.2016.06.010_bib11","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1016\/j.leukres.2014.07.003","article-title":"Outcome prediction by the transcript level of BCR-ABL at 3 months in patients with chronic myeloid leukemia treated with imatinib\u2013a single institution historical experience","volume":"38","author":"Yin","year":"2014","journal-title":"Leuk Res"},{"key":"10.1016\/j.clml.2016.06.010_bib12","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1158\/0008-5472.CAN-10-1066","article-title":"BCR\/ABL stimulates WRN to promote survival and genomic instability","volume":"71","author":"Slupianek","year":"2011","journal-title":"Cancer Res"},{"key":"10.1016\/j.clml.2016.06.010_bib13","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1038\/leu.2012.294","article-title":"BCR-ABL1 kinase inhibits uracil DNA glycosylase UNG2 to enhance oxidative DNA damage and stimulate genomic instability","volume":"27","author":"Slupianek","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2016.06.010_bib14","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1182\/blood-2011-08-358135","article-title":"Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience","volume":"119","author":"Kantarjian","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clml.2016.06.010_bib15","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1038\/sj.leu.2403861","article-title":"Induction of centrosome and chromosome aberrations by imatinib in\u00a0vitro","volume":"19","author":"Fabarius","year":"2005","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2016.06.010_bib16","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.3324\/haematol.2011.056721","article-title":"Analysis of outcomes in adolescents and young adults with chronic myelogenous leukemia treated with upfront tyrosine kinase inhibitor therapy","volume":"97","author":"Pemmaraju","year":"2012","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2016.06.010_bib17","doi-asserted-by":"crossref","first-page":"428","DOI":"10.3109\/01443615.2013.769940","article-title":"Cancer of cervical stump diagnosed in a woman with chronic myelogenous leukaemia","volume":"33","author":"Dogan","year":"2013","journal-title":"J\u00a0Obstet Gynaecol"},{"key":"10.1016\/j.clml.2016.06.010_bib18","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1002\/ajh.20451","article-title":"Granulocytic sarcoma giant in chronic myeloid leukemia during imatinib mesylate therapy","volume":"81","author":"Ros\u00e1rio Cavalheiro Rde","year":"2006","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2016.06.010_bib19","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1111\/ced.12388","article-title":"Multiple squamous cell carcinomas following introduction of nilotinib","volume":"39","author":"Peters","year":"2014","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.clml.2016.06.010_bib20","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1080\/10428190701297360","article-title":"Philadelphia-negative secondary acute myeloid leukaemia during imatinib treatment for chronic phase chronic myeloid leukaemia","volume":"48","author":"Ross","year":"2007","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2016.06.010_bib21","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1007\/s00277-012-1477-3","article-title":"Philadelphia-negative acute promyelocytic leukemia in a patient with chronic myeloid leukemia in complete cytogenetic response after treatment with tyrosine kinase inhibitor","volume":"91","author":"Inokura","year":"2012","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2016.06.010_bib22","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1034\/j.1600-0609.2003.00044.x","article-title":"Squamous cutaneous epithelial cell carcinoma in two CML patients with progressive disease under imatinib treatment","volume":"70","author":"Baskaynak","year":"2003","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.clml.2016.06.010_bib23","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1038\/sj.leu.2403874","article-title":"Unexpected occurrence of second malignancies in patients treated with interferon followed by imatinib mesylate for chronic myelogenous leukemia","volume":"19","author":"Roy","year":"2005","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2016.06.010_bib24","doi-asserted-by":"crossref","first-page":"256","DOI":"10.4149\/neo_2011_03_256","article-title":"Incidence of second malignancies during treatment of chronic myeloid leukemia with tyrosine kinase inhibitors in the Czech Republic and Slovakia","volume":"58","author":"Voglova","year":"2011","journal-title":"Neoplasma"},{"key":"10.1016\/j.clml.2016.06.010_bib25","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1182\/blood.V92.5.1541","article-title":"The Italian Cooperative Study Group on Chronic Myeloid Leukemia. Long-term follow-up of the Italian trial of interferon-alpha versus conventional chemotherapy in chronic myeloid leukemia","volume":"92","year":"1998","journal-title":"Blood"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S215226501630115X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S215226501630115X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:27:27Z","timestamp":1761870447000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S215226501630115X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10]]},"references-count":25,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2016,10]]}},"alternative-id":["S215226501630115X"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2016.06.010","relation":{},"ISSN":["2152-2650"],"issn-type":[{"type":"print","value":"2152-2650"}],"subject":[],"published":{"date-parts":[[2016,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Incidence of Second Malignancies of Chronic Myeloid Leukemia During Treatment With Tyrosine Kinase Inhibitors","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2016.06.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}